Literature DB >> 19724981

Duloxetine serum concentrations and clinical effects. Data from a therapeutic drug monitoring (TDM) survey.

C Waldschmitt1, F Vogel, B Pfuhlmann, C Hiemke.   

Abstract

INTRODUCTION: The aim of this study was to relate drug concentrations in serum and clinical effects in patients treated with the new antidepressant duloxetine.
METHODS: Data were obtained from a newly established therapeutic drug monitoring (TDM) survey. Duloxetine was measured using HPLC with UV detection and clinical effects by the clinical global impressions (CGI) scale for improvement.
RESULTS: The study included 103 depressed inpatients (69% female). Patients under duloxetine monotherapy who were very much improved according to CGI had significantly (p<0.05) higher serum levels than patients with moderate, minimal or lacking improvement (mean+/-SD and range, 93+/-53 ng/mL and 30-182 ng/mL and 47+/-39 ng/mL and 5-178 ng/mL, respectively). Daily doses were similar in the two groups (76+/-27 vs. 83+/-27 mg/d). Receiver operating characteristics (ROC) curve analysis revealed significant predictive properties of duloxetine serum levels (p=0.011) for improvement with a lower threshold concentration of duloxetine of 58 ng/mL. DISCUSSION: The findings indicate that therapeutic drug monitoring of duloxetine and titration to steady state serum concentrations above 58 ng/mL is useful for treatment optimization. Georg Thieme Verlag KG Stuttgart - New York.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19724981     DOI: 10.1055/s-0029-1220890

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  4 in total

Review 1.  Duloxetine: clinical pharmacokinetics and drug interactions.

Authors:  Mary Pat Knadler; Evelyn Lobo; Jill Chappell; Richard Bergstrom
Journal:  Clin Pharmacokinet       Date:  2011-05       Impact factor: 6.447

2.  Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study.

Authors:  Dara J Sakolsky; James M Perel; Graham J Emslie; Gregory N Clarke; Karen Dineen Wagner; Benedetto Vitiello; Martin B Keller; Boris Birmaher; Joan Rosenbaum Asarnow; Neal D Ryan; James T McCracken; Michael J Strober; Satish Iyengar; Giovanna Porta; David A Brent
Journal:  J Clin Psychopharmacol       Date:  2011-02       Impact factor: 3.153

3.  Determination of Patient Adherence for Duloxetine in Urine.

Authors:  Haley A Mulder; Greg L McIntire; Frank N Wallace; Justin L Poklis
Journal:  J Anal Toxicol       Date:  2022-10-14       Impact factor: 3.220

Review 4.  Advances in Precision Health and Emerging Diagnostics for Women.

Authors:  Megan B Fitzpatrick; Avnesh S Thakor
Journal:  J Clin Med       Date:  2019-09-23       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.